Pinealon Peptide Dosage & Reconstitution Guide (Neuroprotective Protocol)
Pinealon
Pinealon (Glu-Asp-Arg, also called EDR) is a synthetic tripeptide developed within the Khavinson short-peptide bioregulator research program. It has been investigated primarily for neuronal stress-response, gene-expression, oxidative-stress, cognitive, and brain-aging pathways. Most mechanistic evidence comes from cellular and animal studies, while limited human research has evaluated Pinealon in older adults and neurologic contexts.
How It Works
Gene-Expression + Cellular Stress Research → Neuronal Signaling → Neuroprotection + Cognitive Research
Pinealon has been studied for effects on neuronal gene expression, oxidative-stress responses, apoptosis-related pathways, and other mechanisms involved in neuronal function. Preclinical research has reported neuroprotective effects, but these mechanisms should not be interpreted as proof of cognitive enhancement or brain rejuvenation in humans.
Pinealon is a short neuroactive tripeptide studied primarily in neuronal and brain-aging research.
Published evidence includes cellular, animal, and limited human research.
Short treatment periods are commonly discussed, but no universal human cycle or dose-escalation schedule has been established.
Timing, route, dose, and duration shown on this page should be understood as research-use frameworks rather than standardized clinical instructions.
Pinealon Research-Use Framework
Important Evidence Distinction:
Pinealon has limited human research history, but the dose progression shown below has not been established through modern human pharmacokinetic, dose-finding, or efficacy trials. The amounts are presented as a research-use framework rather than a validated clinical titration schedule.
Pinealon has limited human research history, but the dose progression shown below has not been established through modern human pharmacokinetic, dose-finding, or efficacy trials. The amounts are presented as a research-use framework rather than a validated clinical titration schedule.
20 mg Vial + 3.0 mL BAC Water → 6.67 mg/mL → 1 Unit ≈ 66.7 mcg
Example Research-Use Setup
Vial
20 mg
Water
3.0 mL bacteriostatic water
Concentration
6.67 mg/mL
Conversion
1 unit ≈ 66.7 mcg
Days 1–5
Starting Phase
Dose
1,000 mcg / 1 mg
Units
≈ 15 units
Volume
≈ 0.15 mL
Frequency
Once daily
Days 6–14
Build Phase
Dose
1,500 mcg / 1.5 mg
Units
≈ 22.5 units
Volume
≈ 0.225 mL
Frequency
Once daily
Days 15–20
Higher Research-Use Range
Dose
2,000 mcg / 2 mg
Units
≈ 30 units
Volume
≈ 0.30 mL
Frequency
Once daily
Research-Use Duration
Example Cycle
10–20 days
Optional Extension
Up to 28 days
Repeat Interval
No universal human interval established
Simple Approach:
Pinealon is commonly discussed in short research-use periods rather than prolonged continuous administration. The framework shown here gradually increases the displayed amount over a defined period, but no standardized human dose-escalation schedule has been established.
Pinealon is commonly discussed in short research-use periods rather than prolonged continuous administration. The framework shown here gradually increases the displayed amount over a defined period, but no standardized human dose-escalation schedule has been established.
What the Research Actually Shows
Published Evidence Context
Pinealon / EDR has been studied in cellular and animal models involving oxidative stress, neuronal survival, gene expression, neuroplasticity, and cognitive function.
Limited human research has evaluated Pinealon in older adults and in neurologic or age-related clinical contexts.
A small 2015 human study involving 32 adults with chronic polymorbidity and organic brain syndrome in remission reported changes in central-nervous-system and biological-age-related measures.
That study was small and does not establish a modern standardized Pinealon dose, titration schedule, cycle length, or repeat interval.
Mechanistic research has linked EDR with regulation of neuronal gene expression, apoptosis-related pathways, oxidative-stress responses, and neuroprotective signaling.
Published evidence does not establish the 1 mg → 1.5 mg → 2 mg progression shown elsewhere on this page as a validated human titration schedule.
Why this matters:
Pinealon has more human research history than many experimental peptides, but the evidence base remains small and is not equivalent to a modern dose-finding program. The research-use protocol shown on this page can still be documented, but it should remain clearly separated from what published human studies have actually established.
Pinealon has more human research history than many experimental peptides, but the evidence base remains small and is not equivalent to a modern dose-finding program. The research-use protocol shown on this page can still be documented, but it should remain clearly separated from what published human studies have actually established.
When & Where to Inject
Route & Injection Sites
Subcutaneous administration is commonly discussed in research-use Pinealon protocols.
Abdomen, thigh, and upper arm are commonly used subcutaneous injection areas.
A standardized human Pinealon injection route and pharmacokinetic profile have not been established through modern clinical trials.
Rotate injection sites to reduce repeated irritation in the same area.
Timing
No clinically established best time of day exists for Pinealon.
Morning administration is commonly discussed in research-use protocols.
Early-afternoon administration is also discussed when morning timing is not practical.
Timing should not be interpreted as a validated clinical requirement because human pharmacokinetic data remain limited.
Reconstitution & Dose Conversion (20 mg Vial)
Reconstitution Setup
Vial
20 mg
Water
3.0 mL bacteriostatic water
Concentration
6.67 mg/mL
Conversion
1 unit ≈ 66.7 mcg
Conversion Reference
15 units ≈ 1 mg
22.5 units ≈ 1.5 mg
30 units ≈ 2 mg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Add the water slowly down the inside wall of the vial
Gently swirl or roll the vial rather than shaking
Allow the contents to dissolve completely
Label with the reconstitution date
Refrigerate after reconstitution
Research Context:
These values are mathematical concentration and syringe conversions. They do not establish an appropriate or clinically validated Pinealon dose.
These values are mathematical concentration and syringe conversions. They do not establish an appropriate or clinically validated Pinealon dose.
Cycle Length & Time Between Cycles
Short Research-Use Period → Reassess → Extended Break → Repeat if Appropriate
Research-Use Cycle Framework
Example Cycle
10–20 days
Optional Extension
Up to 28 days
Commonly Discussed Repeat Interval
Every 2–3 months
Required Human Off-Period
Not established
Research Context:
Short Pinealon courses appear in bioregulator research discussions, but controlled human studies have not established an optimal 10–20 day cycle, a required 8–12 week break, or a specific repeat-cycle interval.
Short Pinealon courses appear in bioregulator research discussions, but controlled human studies have not established an optimal 10–20 day cycle, a required 8–12 week break, or a specific repeat-cycle interval.
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed)
Store frozen or refrigerated
Refrigerated (2–8°C): ~12–24 months
Frozen (−20°C): up to ~2–3 years
Store sealed, dry, and protected from light
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C
Use within ~4 weeks after reconstitution
Do not freeze after mixing
Avoid repeated temperature changes
Best Practice
Keep the vial cold, protected from light, and avoid unnecessary handling. If the solution becomes cloudy, discolored, or develops visible particles, it is safer not to continue using it.
Keep the vial cold, protected from light, and avoid unnecessary handling. If the solution becomes cloudy, discolored, or develops visible particles, it is safer not to continue using it.
Cycle Length & Time Between Cycles
Short Research-Use Period → Reassess → Extended Break → Repeat if Appropriate
Research-Use Cycle Framework
Example Cycle
10–20 days
Optional Extension
Up to 28 days
Commonly Discussed Repeat Interval
Every 2–3 months
Required Human Off-Period
Not established
Time Between Research Periods
Commonly Discussed Break
2–3 months
The break period is a research-use convention rather than a clinically validated requirement.
Reassessment can include cognitive response, sleep, tolerability, and any unexpected effects before considering another research period.
Controlled human studies have not established an optimal Pinealon repeat-cycle interval.
Why reassess?
Pinealon is commonly discussed in short research-use periods, but the 10–20 day cycle and 2–3 month break are not established clinical standards. Limited human research does not define a required washout period or repeat schedule, so these intervals should be treated as research-use frameworks.
Pinealon is commonly discussed in short research-use periods, but the 10–20 day cycle and 2–3 month break are not established clinical standards. Limited human research does not define a required washout period or repeat schedule, so these intervals should be treated as research-use frameworks.
Reasons to Reassess or Pause
The defined research-use period has ended
No meaningful change is being observed for the research goal
Sleep quality or alertness changes unexpectedly
Injection-site irritation becomes persistent
New or unexpected neurologic or systemic symptoms occur
Monitoring During Use
Cognitive clarity and focus
Mental energy levels
Sleep quality
Memory function
Any new or unexpected neurologic or systemic symptoms
Injection-site tolerance
Benefits
Cellular and animal studies have demonstrated neuroprotective effects under oxidative and metabolic stress
Preclinical research has investigated effects on neuronal gene expression and apoptosis-related pathways
Animal studies have evaluated learning, memory, and cognitive outcomes in several disease and stress models
Limited human research has reported changes in central-nervous-system and age-related measures
Cognitive enhancement, brain rejuvenation, and broad anti-aging benefits have not been established in large controlled human trials
Potential Side Effects
Injection-site irritation or sensitivity may occur with subcutaneous research-use administration
Human adverse-effect frequency has not been well established
Neurologic, sleep, or alertness responses may vary between individuals
Long-term safety of repeated Pinealon treatment cycles remains uncertain
Important Notes
Pinealon is the synthetic tripeptide Glu-Asp-Arg, also referred to as EDR.
Published research includes cellular, animal, and limited human studies, but the overall human evidence base remains small.
The 1–2 mg daily ranges and 10–20 day cycle shown on this page represent research-use frameworks rather than standardized clinical dosing guidelines.
Human research findings should not be generalized to healthy-adult cognitive enhancement or anti-aging use.
No universal human dose, administration schedule, cycle length, repeat interval, or required off-period has been established.
Long-term human safety and pharmacokinetic data remain limited.
Important Disclaimer
Pinealon is not FDA-approved and is intended for research purposes only.
Research & References
Primary Research
- Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative Processes. Rejuvenation Research. 2011.
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2020.
- Mendzheritsky AM, Karantysh GV, Ryzhak GA, Prokofiev VN. Pinealon and Cortexin Influence on Behavior and Neurochemical Processes in 18-Month Aged Rats Within Hypoxia and Hypothermia. Advances in Gerontology. 2015.
Research Note: Dosing and reconstitution details reflect common research-context handling practices for Pinealon. The evidence base comes largely from Russian-language preclinical and small clinical-use research; large independent human trials are limited.
Comments
Post a Comment